Kettner et al. found that targeting interleukin 6 (IL6)/signal transducer and activator of transcription 3 (STAT3) and DNA repair deficiency using a combination STAT3 and poly(ADP-ribose) polymerase (PARP) inhibitor could effectively treat palbociclib-resistant ER+ BC [173]. Here, STAT3 is linked to breast cancer.